HUYA Bioscience International
Shanghai Zhangjiang, Hi-Tech Park
780 Cailun Road, Suite 805
Pudong, Shanghai 201203
China
沪亚国际
中国上海浦东新区张江高新园区蔡伦路780 号805室
邮编:201203
Tel: +86 21 5132 3312
Fax: +86 21 5132 3312
HUYA Bioscience International
Beijing Office
Room 505A, Jialong International Tower, NO.19 Chaoyang Gongyuan Road
Chaoyang District, Beijing 100026
China
北京市朝阳区朝阳公园路19号佳隆国际大厦505A室
邮编：100026
Tel: +86 10 8269 6766
HUYA Bioscience International
Chengdu Office
Suite B-B-33-1, Building 1, Nan Yan Xian, Tian Fu Ave.
Hi-tech Incubation Park, Chengdu Hi-tech Zone
Chengdu 610041
China
成都市高新区天府大道南延线高新孵化园1号楼B-B-33-1室
邮编:610041
Tel: +86 28 6607 0098
HUYA Bioscience International
Suzhou Office
Room H46 3F, A1 Building, 218 Xinghu Str.
Suzhou Biobay Park
Suzhou 215021
China
苏州市工业园区星湖街218号生物纳米园A1北座3楼H46
邮编 : 215021
HUYA Bioscience International
Guangzhou Office
Room 204, Building 23-1, 100 Xianlie Zhong Road
Guangzhou 510070
China
广州市先烈中路100号
23-1号楼204室
邮编:510070
Tel: +86 20 8768 0586
HUYA Bioscience International
Hangzhou Office
Room B0609, Building 2, High-tech Business Incubator, #452 Six Avenue
Hangzhou Xiasha Economic Technological Development Zone
Hangzhou 310018
China
杭州下沙经济技术开发区6号大街452号高科技企业孵化器2号楼B0609室
邮编:310018
Tel: +86 571 8817 7280
HUYA Bioscience International
Shenzhen Office
Room 314, 3F, C1 Integrated Service Building
Southern Area of Hi-Tech Industrial Park, Nanshan District
Shenzhen 518057
China
深圳市南山区科技园南区C1综合服务楼3楼314室
邮编:518057
HUYA Bioscience International
Wuhan Office
Room 405, Building C8, Optics Valley Seven Road
Biomedical Park, Wuhan East Lake High-Tech Zone
Wuhan 430079
China
武汉市东湖高新区光谷七路生物医药园C8栋405室
邮编:430079
Tel: +86 27 8718 8018
HUYA Bioscience International Announces the Successful Completion of Phase 1 Trial of HBI-3000
/in 2020 /by hwkA5jb3Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation
San Diego, CA, USA – February 28, 2020 HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF).
HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries
/in 2007 /by hwkA5jb3Meiji Seika Pharma to Commercialize HUYABIO’s Product in Lymphoma
San Diego, CA, USA – January 8, 2020 – HUYA Bioscience International CEO & Executive Chair, Dr. Mireille Gillings announced the appointment of Meiji Seika Pharma (Meiji) as an exclusive distributor for its lymphoma product, HBI-8000, in Japan. Meiji also acquired exclusive rights for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.
HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors
/in 2018 /by hwkA5jb3San Diego, CA, USA – June 4, 2018 – HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it is at a key stage in the company’s development of HBI-8000, HUYA’s lead novel epigenetic drug with important immunomodulatory properties. HUYA is conducting a Phase 2 trial of HBI-8000 in the US, investigating efficacy and safety in combination with nivolumab for the treatment of solid tumors.
HUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOP
/in 2017 /by hwkA5jb3San Diego, CA, USA – July 10, 2017 – HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with Suzhou BioTOP Technical Service Co., Ltd. (referred to as BioTOP). The collaboration will focus on promoting the development of biomedical innovations from companies and research organizations in Suzhou BioBay that help to meet the increasing demand to fill global pharmaceutical pipelines.
HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration
/in 2017 /by huyausaSan Diego, CA, USA – January 18, 2017 –HUYA Bioscience International (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.
HUYA Bioscience International Sponsors 12th Annual Scrip Awards ‘Best New Drug’ Category
/in 2016 /by hwkA5jb3San Diego, CA, USA – December 14, 2016 – For the second straight year, HUYA Bioscience International (HUYA) was a proud sponsor of the Best New Drug category at the Annual Scrip Awards.
HUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016
/in 2016 /by huyausaRecognized for Visionary Leadership Within Asia’s Pharmaceutical Industry
San Diego, CA, USA – March 24, 2016 –HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9th BioPharma Asia Convention 2016.
HUYA Bioscience International Celebrates 10 Years in China
/in 2016 /by huyausaBiopharma Company with Joint HQ in Shanghai & San Diego Commemorates a Decade of Innovation
Shanghai, China – March 22, 2016 –HUYA Bioscience International (HUYA) celebrated the 10th anniversary of the opening of its first offices in China with a gala dinner at the ‘M on the Bund’ restaurant in Puxi, Shanghai.
HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University
/in 2016 /by huyausaInhibitors of indoleamine 2,3-dioxygenase to be Developed for Oncology Therapy
San Diego, CA, USA – March 15, 2016 –HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.
HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan
/in 2015 /by huyausaHBI-8000 granted orphan drug designation for peripheral T-cell lymphoma in Japan
San Diego, CA, USA – December 22, 2015 –HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).